Medexus Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc stock price live, this page displays TSX MDP stock exchange data. View the MDP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Medexus Pharmaceuticals Inc real time stock price chart below.
What Is the Medexus Pharmaceuticals Inc Stock Price Today?
The Medexus Pharmaceuticals Inc stock price today is 2.69.
What Is the Stock Symbol for Medexus Pharmaceuticals Inc?
The stock symbol for Medexus Pharmaceuticals Inc is "MDP."
What Stock Exchange Does Medexus Pharmaceuticals Inc Trade On?
Medexus Pharmaceuticals Inc is listed and trades on the Toronto stock exchange.
Is Medexus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Medexus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDP quote. (ISIN: CA58410Q2036)
What Is the Medexus Pharmaceuticals Inc Stock Price Today?
The Medexus Pharmaceuticals Inc stock price today is 2.69.
What Is the Stock Symbol for Medexus Pharmaceuticals Inc?
The stock symbol for Medexus Pharmaceuticals Inc is "MDP."
What Stock Exchange Does Medexus Pharmaceuticals Inc Trade On?
Medexus Pharmaceuticals Inc is listed and trades on the Toronto stock exchange.
Is Medexus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Medexus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDP quote. (ISIN: CA58410Q2036)
2.69
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.69
2.77
52 wk Range
1.50
5.56
MDP Scorecard
Full Analysis
Net income is expected to grow this year
MDP is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.692.77
52 wk Range
1.505.56
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MDP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
6.46
Upside
+140.31%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Medexus Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Medexus Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Medexus Pharmaceuticals Inc Company Profile
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
Compare MDP to Peers and Sector
Metrics to compare | MDP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.4x | −0.5x | −0.5x | |
PEG Ratio | −0.38 | −0.01 | 0.00 | |
Price/Book | 1.9x | 0.3x | 2.6x | |
Price / LTM Sales | 0.6x | 1.8x | 3.0x | |
Upside (Analyst Target) | 123.0% | 123.3% | 53.7% | |
Fair Value Upside | Unlock | 15.5% | 8.4% | Unlock |
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.46
(+140.31% Upside)
Earnings
Latest Release
Feb 05, 2025
EPS / Forecast
0.03 / 0.05
Revenue / Forecast
29.99M / 41.59M
FAQ
What Is the Medexus Pharma (MDP) Stock Price Today?
The Medexus Pharma stock price today is 2.69
What Stock Exchange Does Medexus Pharma Trade On?
Medexus Pharma is listed and trades on the Toronto Stock Exchange stock exchange.
What Is the Stock Symbol for Medexus Pharma?
The stock symbol for Medexus Pharma is "MDP."
What Is the Medexus Pharma Market Cap?
As of today, Medexus Pharma market cap is 86.77M.
What Is Medexus Pharma's Earnings Per Share (TTM)?
The Medexus Pharma EPS (TTM) is 0.15.
From a Technical Analysis Perspective, Is MDP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.